IL164161A0 - Therapeutic methods and uses of sapogenins and their derivatives - Google Patents

Therapeutic methods and uses of sapogenins and their derivatives

Info

Publication number
IL164161A0
IL164161A0 IL16416103A IL16416103A IL164161A0 IL 164161 A0 IL164161 A0 IL 164161A0 IL 16416103 A IL16416103 A IL 16416103A IL 16416103 A IL16416103 A IL 16416103A IL 164161 A0 IL164161 A0 IL 164161A0
Authority
IL
Israel
Prior art keywords
derivatives
therapeutic methods
sapogenins
cognitive
neurodegeneration
Prior art date
Application number
IL16416103A
Other languages
English (en)
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP020101170A external-priority patent/AR033079A1/es
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of IL164161A0 publication Critical patent/IL164161A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
IL16416103A 2002-03-27 2003-03-27 Therapeutic methods and uses of sapogenins and their derivatives IL164161A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ARP020101170A AR033079A1 (es) 2001-03-28 2002-03-27 Derivados de sapogeninas, sintesis y uso, y metodos en base a su uso
US36817802P 2002-03-28 2002-03-28
PCT/GB2002/001578 WO2002079221A2 (en) 2001-03-28 2002-03-28 Sapogenin derivatives, their synthesis and use
PCT/GB2003/001380 WO2003082893A2 (en) 2002-03-27 2003-03-27 Theraputic methods and uses of sapogenins and their derivatives

Publications (1)

Publication Number Publication Date
IL164161A0 true IL164161A0 (en) 2005-12-18

Family

ID=30001210

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16416103A IL164161A0 (en) 2002-03-27 2003-03-27 Therapeutic methods and uses of sapogenins and their derivatives

Country Status (10)

Country Link
KR (1) KR20100093621A (zh)
CN (1) CN1642558B (zh)
AT (1) ATE424211T1 (zh)
IL (1) IL164161A0 (zh)
NZ (2) NZ547897A (zh)
PE (1) PE20040306A1 (zh)
PL (1) PL213697B1 (zh)
RU (1) RU2332999C2 (zh)
TW (1) TWI329016B (zh)
WO (1) WO2003082893A2 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861788B2 (en) * 2003-06-03 2005-03-01 Motorola, Inc. Switchable display/mirror method and apparatus
FR2868700B1 (fr) * 2004-04-09 2008-09-26 Michel Coisy Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie.
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
HUE035328T2 (en) 2005-10-28 2018-05-02 Univ Industry Cooperation Group Kyung Hee Univ Extract from Dioscoreaceae Family Plants and Composition Containing it for Prevention or Treatment of Peripheral Neuropathy
CA2750510A1 (en) 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CA2805693A1 (en) * 2010-07-20 2012-01-26 Phytopharm Plc Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
CN113956315A (zh) 2011-09-08 2022-01-21 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
WO2013149580A1 (en) * 2012-04-03 2013-10-10 Chiming Che Timosaponin compounds
ES2886506T3 (es) 2013-03-13 2021-12-20 Sage Therapeutics Inc Esteroides neuroactivos
CN103232520A (zh) * 2013-05-13 2013-08-07 中国药科大学 一种螺甾类化合物、其制备方法及医药用途
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA2991311A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE053778T2 (hu) 2015-07-06 2021-07-28 Sage Therapeutics Inc Oxiszterinek és ezek alkalmazása
MA54851A (fr) 2015-07-06 2021-12-08 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
PT3436022T (pt) 2016-04-01 2022-07-04 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3481846B1 (en) 2016-07-07 2021-05-12 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
BR112019006365A2 (pt) 2016-09-30 2019-08-06 Sage Therapeutics Inc oxisteróis substituídos c7 e métodos de utilização dos mesmos
EP3529257B1 (en) 2016-10-18 2023-05-10 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP2019532079A (ja) 2016-10-18 2019-11-07 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
CN108264535A (zh) * 2016-12-30 2018-07-10 中国科学院上海药物研究所 一种抗抑郁化合物及其制备方法和应用
RU2635485C1 (ru) * 2017-03-21 2017-11-13 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения атрофии зрительного нерва после черепно-мозговой травмы
CN109988218B (zh) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
EP3572085A1 (en) * 2018-05-25 2019-11-27 Neuro-Sys Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3416112A1 (de) * 1984-04-30 1985-10-31 Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
TW479061B (en) * 1993-12-24 2002-03-11 Mitsubishi Chem Corp Sialic acid derivatives
JPH092957A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 末梢性神経障害の治療、予防薬
JPH092956A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 神経障害の治療、予防薬
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
CN1198622C (zh) * 1998-03-26 2005-04-27 植物药物公共有限公司 用于治疗阿尔茨海默病的甾类皂苷及其衍生物
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
JP2002030096A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法
AU2003218180B2 (en) * 2002-03-15 2008-03-20 Georgetown University Neuroprotective spirostenol pharmaceutical compositions

Also Published As

Publication number Publication date
RU2332999C2 (ru) 2008-09-10
WO2003082893A2 (en) 2003-10-09
PE20040306A1 (es) 2004-05-29
ATE424211T1 (de) 2009-03-15
PL213697B1 (pl) 2013-04-30
WO2003082893A8 (en) 2003-12-31
NZ547344A (en) 2007-11-30
KR20100093621A (ko) 2010-08-25
CN1642558A (zh) 2005-07-20
NZ547897A (en) 2008-02-29
TW200400042A (en) 2004-01-01
WO2003082893A3 (en) 2004-04-15
TWI329016B (en) 2010-08-21
PL372941A1 (en) 2005-08-08
RU2004130281A (ru) 2006-01-20
CN1642558B (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
IL164161A0 (en) Therapeutic methods and uses of sapogenins and their derivatives
WO2002079221A3 (en) Sapogenin derivatives, their synthesis and use
HK1046912A1 (en) Substituted sapogenins and their use
GB9923076D0 (en) Sapogenin derivatives and their use
PL343508A1 (en) Smilagenin and anzurogenin-d and their use
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
CA2385410A1 (en) Sapogenin derivatives and their use in the treatment of cognitive dysfunction
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
GB9923078D0 (en) Sapogenin derivatives and their use
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
WO2004034889A3 (en) Photodynamic therapy for ocular neovascularization
HRP20041009A2 (en) Theraputic methods and uses of sapogenins and their derivatives
TW200833344A (en) Therapeutic methods and uses of sapogenins and their derivatives
WO2005058911A3 (en) Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
BR0308788A (pt) Processos terapêuticos e usos de sapogeninas e seus derivados
AU2003202255A1 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
MY134920A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
AU2003251734A1 (en) Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve
WO2004073631A3 (en) Combination therapy for the treatment of neoplasms